Form 4: Pfizer CEO Albert Bourla Acquires Phantom Stock Units
Insider Transaction Report
Pfizer's Chairman and CEO, Albert Bourla, acquired 23 phantom stock units at $25.74 each, increasing his beneficial ownership to 743,115 units.
Summary
- Albert Bourla, Chairman and CEO of Pfizer Inc., acquired 23 phantom stock units.
- The transaction occurred on November 28, 2025.
- Each unit represents one phantom share of Pfizer common stock.
- The acquisition price for these units was $25.74 per unit.
- These units were acquired under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
- Following this transaction, Bourla beneficially owns 743,115 phantom stock units.
- These units are settled in cash upon separation from service and can be transferred to an alternative investment account.
Sentiment
Score: 6
Explanation: The acquisition of phantom stock units by the CEO, as part of a deferred compensation plan, is a routine insider transaction. It indicates continued participation in the company's long-term incentive structure but does not signal a significant change in company outlook or performance.
Positives
- Insider acquisition of phantom stock units, indicating continued participation in the company's deferred compensation plan.
- The acquisition price of $25.74 per unit reflects a specific valuation at the time of acquisition.
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- Acquisition of 23 phantom stock units by CEO Albert Bourla under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
Stakeholder Impact
- Shareholders: Minor positive signal from insider participation in compensation, but no direct impact on share price from this routine transaction.
Key Dates
| Date | Description |
|---|---|
| 11/28/2025 | Date of earliest transaction for phantom stock unit acquisition. |
| 12/02/2025 | Date the Form 4 was signed by power of attorney. |
Recommendation
holdThis Form 4 reports a routine acquisition of phantom stock units by Pfizer's CEO as part of a deferred compensation plan. Such transactions are common and do not typically indicate a significant shift in the company's fundamentals or outlook that would warrant a change in investment recommendation. Investors should continue to hold based on broader company performance and market conditions.
Keywords
Pfizer, PFE, Albert Bourla, Insider Trading, Form 4, Phantom Stock Units, Deferred Compensation, CEO, Stock Acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.